Proteostasis Decline and Redox Imbalance in Age-Related Diseases: The Therapeutic Potential of NRF2
Biomolecules · 2025
DOI: 10.3390/biom15010113 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Brigitta Buttari und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular and Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, 00161 Rome, Italy. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Proteostasis, Aging. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 321 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish Ministry of Science, Innovation and Universities, CIBERNED/ISCIII, Autonomous Community of Madrid.
Abstract (Originalsprache)
Nuclear factor erythroid 2-related factor 2 (NRF2) is a master regulator of cellular homeostasis, overseeing the expression of a wide array of genes involved in cytoprotective processes such as antioxidant and proteostasis control, mitochondrial function, inflammation, and the metabolism of lipids and glucose. The accumulation of misfolded proteins triggers the release, stabilization, and nuclear translocation of NRF2, which in turn enhances the expression of critical components of both the proteasomal and lysosomal degradation pathways. This process facilitates the clearance of toxic protein aggregates, thereby actively maintaining cellular proteostasis. As we age, the efficiency of the NRF2 pathway declines due to several factors including increased activity of its repressors, impaired NRF2-mediated antioxidant and cytoprotective gene expression, and potential epigenetic changes, though the precise mechanisms remain unclear. This leads to diminished antioxidant defenses, increased oxidative damage, and exacerbated metabolic dysregulation and inflammation—key contributors to age-related diseases. Given NRF2’s role in mitigating proteotoxic stress, the pharmacological modulation of NRF2 has emerged as a promising therapeutic strategy, even in aged preclinical models. By inducing NRF2, it is possible to mitigate the damaging effects of oxidative stress, metabolic dysfunction, and inflammation, thus reducing protein misfolding. The review highlights NRF2’s therapeutic implications for neurodegenerative diseases and cardiovascular conditions, emphasizing its role in improving proteostasis and redox homeostasis Additionally, it summarizes current research into NRF2 as a therapeutic target, offering hope for innovative treatments to counteract the effects of aging and associated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular and Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, 00161 Rome, Italy.
- Department of Biochemical Sciences "A. Rossi Fanelli", Sapienza University, 00185 Rome, Italy.
- Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), National Institute of Health Carlos III (ISCII…
- Institute of Chemical Biology, National Hellenic Research Foundation, 116 35 Athens, Greece.
- Department of Biotechnology, Institute of Applied Sciences & Humanities, GLA University, Mathura 00185, Uttar Pradesh, India.
- Center for Behavioral Sciences and Mental Health, Istituto Superiore di Sanità, 00161 Rome, Italy.
ORCID-Profile: Brigitta Buttari, Antonella Tramutola, Ana I Rojo, Niki Chondrogianni, Sarmistha Saha, Alessandra Berry, Letizia Giona, Joana P Miranda, Elisabetta Profumo, Sergio Davinelli, Andreas Daiber, Antonio Cuadrado, Fabio Di Domenico
Förderung
- Spanish Ministry of Science, Innovation and Universities
- CIBERNED/ISCIII
- Autonomous Community of Madrid
- Sapienza University of Rome
- Jerome Lejeune Foundation
- Spanish Ministry of Science, Innovation, and Universities
- Sapienza University
Zitieren
APA
Buttari, B., Tramutola, A., Rojo, A. I., Chondrogianni, N., Saha, S., Berry, A., Giona, L., Miranda, J. P., Profumo, E., Davinelli, S., Daiber, A., Cuadrado, A., & Di Domenico, F. (2025). Proteostasis Decline and Redox Imbalance in Age-Related Diseases: The Therapeutic Potential of NRF2. Biomolecules. https://doi.org/10.3390/biom15010113
Vancouver
Buttari B, Tramutola A, Rojo AI, Chondrogianni N, Saha S, Berry A, et al. Proteostasis Decline and Redox Imbalance in Age-Related Diseases: The Therapeutic Potential of NRF2. Biomolecules. 2025. doi:10.3390/biom15010113
BibTeX
@article{Buttari2025,
author = {Buttari, Brigitta and Tramutola, Antonella and Rojo, Ana I and Chondrogianni, Niki and Saha, Sarmistha and Berry, Alessandra and Giona, Letizia and Miranda, Joana P and Profumo, Elisabetta and Davinelli, Sergio and Daiber, Andreas and Cuadrado, Antonio and Di Domenico, Fabio},
title = {Proteostasis Decline and Redox Imbalance in Age-Related Diseases: The Therapeutic Potential of NRF2},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15010113}
}
EUVIMED